Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The query refers to a broad biological process—modulation of immune responses via alteration of the gut microbiota and anti-inflammatory effects of phytochemicals such as β-glucan and flavonoids—not a single discrete molecular target. β-Glucans are varied polysaccharides found in cereals, yeast, fungi, and bacteria. They exert immunomodulatory and anti-inflammatory effects primarily through interaction with specific receptors on immune cells, namely Dectin-1 (a C-type lectin receptor), complement receptor 3 (CR3), and Toll-like receptors (TLR2, TLR4, TLR6)[1][3][5]. Binding of β-glucans to these pattern-recognition receptors (PRRs) triggers cellular signaling pathways that enhance phagocytosis, stimulate cytokine production, and regulate both innate and adaptive immunity[1][5][6]. The immunological effects of β-glucans are further influenced by interactions with the gut microbiota, where microbial fermentation may produce metabolites (such as butyrate and lactic acid) associated with anti-inflammatory activity and improved metabolic health[2]. However, the target listed—"Immune response modulation via gut microbiota alteration and anti-inflammatory effects of phytochemicals such as beta-glucan and flavonoids"—is too broad and functionally refers to multiple molecular targets (a set of PRRs) and physiological effects, not a single defined molecule or receptor. Important caveat: The target described is not a canonical therapeutic target (such as a defined enzyme, receptor, or transporter) but a complex physiological mechanism involving several receptor types (notably Dectin-1, CR3, and TLRs) and cellular pathways. Therefore, structured target information cannot be assigned to a single molecule; the entry is best classified as incorrect or overly broad[1][3][5].
Ligand-induced activation of innate immune receptors (e.g., Dectin-1, CR3, TLR2/4/6), leading to downstream immune cell activation and anti-inflammatory or immune-stimulating effects
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on β-Glucan immunomodulatory receptors (primarily Dectin-1, complement receptor 3, and Toll-like receptors).